Design and synthesis of lipophilic phosphoramidate d4T-MP prodrugs expressing high potency against HIV in cell culture: Structural determinants for in vitro activity and QSAR

Journal of Medicinal Chemistry

Volumn 42, Issue 20, 1999, Pages 4122-4128

  Siddiqui, Adam Q ^a   McGuigan, Christopher ^a   Ballatore, Carlo ^a   Zuccotto, Fabio ^a   Gilbert, Ian H ^a   De Clercq, Erik ^b   Balzarini, Jan ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NUCLEOTIDE DERIVATIVE; PHOSPHORAMIDIC ACID; PHOSPHORAMIDIC ACID DERIVATIVE; PRODRUG; STAVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LIPOPHILICITY; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

AMIDES; ANTI-HIV AGENTS; CELL LINE; HIV-1; HIV-2; PHOSPHORIC ACIDS; PRODRUGS; STAVUDINE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033533881     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9807104     Document Type: Article

References (32)

1. De Clercq, E. In search of a Selective Antiviral Chemotherapy. Clin. Microbiol. Rev. 1997, 10, 674-693.
2. Mitsuya, H.; Weinhold, K. J.; Furman, P. A.; St Clair, M. H.; Nusinoff-Lehman, S.; Gallo, R. C.; Bolognesi, D.; Barry, D. W.; Broder, S. 3́-Azido-3́-deoxythymidme (BWA509U): An agent that inhibits the infectivity and cytopathic effect of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Scid. U.S.A. 1985, 82, 7096-7100.
3. Mitsuya, H.; Broder, S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus, type III/lymphadenopathy-associated virus (HTLV III/LAV) by 2́,3́-didoxynucleosides. Proc. Natl. Acad. Sci U.S.A. 1986, 83, 1911-1915.
4. Balzarini, J.; Kang, G.-J.; Dalal, M.; Herdewijn, P.; De Clercq, E.; Broder, S.; Johns, D. G. The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2′,3′-didehydro-2′,3′-dideoxyribonucleosides. A comparison with their parental 2′,3′-dideoxyribonucleosides. Mol. Pharmacol. 1987, 32, 162-167.
5. Herdewijn, P.; Balzarini, J.; De Clercq, E.; Pauwels, R.; Baba, M.; Broder, S.; Vanderhaeghe, H. 3′-Substituted 2′,3′-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents. J. Med. Chem. 1987, 30, 1270-1278.
6. Balzarini, J.; Baba, M.; Pauwels, R.; Herdewijn, P.; De Clercq, E. Anti-retrovirus activity of 3′-fluoro-and 3′-azido-substituted pyrimidine 2′,3′-dideoxynucleoside analogues. Biochem. Pharmacol. 1988, 37, 2847-2856.
7. Baba, M.; Pauwels, R.; Herdewifn, P.; De Clercq, E.; Desmyter, J.; Vandeputte, M. Both 2′,3′-dideoxythmidine and its 2′,3′-unsaturated derivative (2′,3′-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. Biochem. Biophys. Res. Commun. 1987, 142, 128-134.
8. Mansuri, M. M.; Hitchcock, M. J. M.; Buroker, R. A.; Bregman, C. L.; Ghazzouli, I.; Desiderio, J. V.; Starrett Jr., J. E.; Sterzycki, R. Z.; Martin, J. C. Properties and Mouse Toxicities of 3 Thymidine Analogues Active Against Human-Immunodeficiency-Virus. Antimicrob. Agents Chemother. 1990, 17, 637-641.
9. Furman, P. A.; Fyfe, J. A.; St. Clair, M. H.; Weinhold, K.; Rideout, J. L.; Freeman, J. A.; Lehrman, S. N.; Bolognesi, D. P.; Broder, S.; Mitsuya, H.; Barry, D. W. Phosphorylation of 3′-Azido-3′-dideoxythymidine and Selective Interaction of the 5′-Triphosphate with Human Immunodeficiency Virus Reverse Transcriptase. Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 8333-8337.
10. Balzarini, J.; Herdewijn, P.; De Clercq, E. Differential patterns of intracellular metabolism of 2′,3′-didehydro-2′,3′-dideoxythymidine and 3′-azido-2′,3′-dideoxythymidine, two potent antihuman immunodeficiency virus compounds. J. Biol. Chem. 1989, 264, 6127-6133.
11. Balzarini, J.; Cooney, D. A.; Dalal, M.; Kang, G.-J.; Cupp, J. E.; De Clercq, E.; Broder, S.; Johns, D. G. 2′,3′-Dideoxycytidine: regulation of its metabolism and anti-retroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis. Mol. Pharmacol. 1987, 32, 798-806.
12. Starnes, M. G.; Cheng, Y.-C. Cellular metabolism of 2′,3′-Dideoxycytidine, a compound active against human immunodeficiency virus in vitro. J. Biol. Chem. 1987, 32, 798-806.
13. Hao, Z.; Cooney, D. A.; Farquhar, D.; Perno, C. F.; Zhang, K.; Masood, R.; Wilson, Y.; Hartman, N. R.; Balzarini, J.; Johns, D. G. Potent chain termination activity and selective inhibition of human immunodeficiency virus reverse transcriptase by 2′,3′-dideoxyuridine-5′-triphosphate. Mol. Pharmacol. 1990, 37, 157-163.
14. Johnson, M. A.; Ahluwalia, G.; Connelly, M. C.; Cooney, D. A.; Broder, S.; Johns, D. G.; Fridland, A. Metabolic pathways for the activation of the antiretroviral agent 2′,3′-dideoxyadenosine in human lymphoid cells. J. Biol. Chem. 1988, 263, 15354-15357.
15. Johnson, M. A.; Fridland, A. Phosphorylation of 2′,3′-dideoxyinosine by cytosolic 5′-nucleotidase of human lymphoid cells. Mol. Pharmacol. 1989, 36, 291-295.
16. Jones, R. J.; Bischofberger, W. Minireview - Nucleotide Prodrugs. Antiviral Res. 1995, 27, 1-17.
17. Meier, C. Pro-Nucleotides Recent Advances in the Design of Efficient Tools for the Delivery of Biologically Active Nucleosides Monophosphates. Synlett 1998, 233-242.
18. McGuigan, C.; Cahard, D.; Sheeka, H. M.; De Clercq, E.; Balzarini, J. Phosphoramidate derivatives of d4T with improved anti-HIV efficacy retain full activity in thymidine kinase-deficient cells. Bioorg. Med. Chem. Lett. 1996, 6, 1183-1186.
19. McGuigan, C.; Cahard, D.; Sheeka, H. M.; De Clercq, E.; Balzarini, J. Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite. J. Med. Chem. 1996, 39, 1748-1753.
20. Balzarini, J.; Kruining, J.; Wedgwood, O.; Fannecouque, C.; Aquaro, S.; Perno, C. F.; Naesens, L.; Witvrouw, M.; Heijtink, R.; De Clercq, E.; McGuigan, C. Conversion of 2′,3′-dideoxyadenosine (ddA) and 2′,3′-didehydro-2′,3′-dideoxyadenosine (d4A) to their corresponding aryloxyphosphoramidate derivatives markedly potentiates their activity against human immunodeficiency virus and hepatitis B virus. FEBS Lett. 1997, 470, 324-328.
21. Siddiqui, A. Q.; McGuigan, C.; Ballatore, C.; De Clercq, E.; Balzarini, J. The Presence of Substituents on the Aryl Phosphoramidate Derivative of d4T Enhances Anti-HIV Efficacy in Cell Culture: A Structure-Activity Relationship. J. Med. Chem. 1999, 42, 393-399.
22. Horwitz, J. P.; Chua, J.; DaRooge, M. A.; Noel, M.; Klindt, I. L. Nucleosides. IX. The formation of 2′,3′-unsaturated pyrimidine nucleosides via a novel β-elimination rection. J. Org. Chem. 1996, 31, 205-211.
23. Mansuri, M. M.; Starrett Jr., J. E.; Ghazzouli, I.; Hitchcock, M. J. M.; Sterzycki, R. Z.; Brankovan, V.; Lin, T. S.; August, E. M.; Prussoff, W. H.; Sommadossi, J. P.; Martin, J. C. 1-(2′,3′-dideoxyβ-D-glycero-pent-2-enfuranosyl)thyimine. A highly Potent and Selective Anti-HIV Agent. J. Med. Chem. 1989, 32, 462-446.
24. McGuigan, C.; Cahard, D.; Saigado, A.; De Clercq, E.; Balzarini, J. Phosphoramidates as potent prodrugs of anti-HIV nucleotides: studies in the amino region. Antiviral Chem. Chemother. 1996, 7, 31-36
25. McGuigan, C.; Pathirana, R. N.; Balzarini, J.; De Clercq, E. Intracellular delivery of bioactive AZT nucleotides by aryl phosphate derivatives of AZT. J. Med. Chem. 1993, 36, 1048-1052.
26. Fujita, T.; Miyoshi, H. Quantitative analyses of the uncoupling activity of substituted phenols with mitochondria from muscles of house flies. Biochim. Biophys. Acta 1988, 935, 312-321.
27. Fujita, T.; Nishioka, T.; Miyoshi, H. Quantitative Relationship Between Protonophoric and Uncoupling Activities of Substituted Phenols. Biochim. Biophys. Acta 1987, 891, 194-204.
28. Valette, G.; Pompon, A.; Girardet, J. L.; Cappellacci, L.; Franchetti, P.; Grifantini, M.; LaColla, P.; Loi, A. G.; Perigaud, C.; Gosselin, G.; Imbach, J. L. Decomposition pathways and in vitro HIV inhibitory effects of isoddA pronucleotides - toward a rational approach for intracellular delivery of nucleoside 5′-monophosphates. J. Med. Chem. 1996, 39, 1981-1990.
29. Topliss, J. G. Utilization of Operational Schemes for Analogue Synthesis in Drug Design. J. Med. Chem. 1972, 15, 1006-1011.
30. Hansch, C.; Leo, A. Substitution Constants for Correlation Analysis in Chemistry and Biology; Wiley-Interscience: New York, 1979.
31. Hansch, C.; Leo, A.; Unger, S. H.; Kim, K. H.; Nikaitani, D.; Lien, E. J. "Aromatic" Substituent Constants for Structure-Activity Correlations. J. Med. Chem. 1973, 16, 1207-1216.
32. SYBYL, version 6.5; Tripos Associates: St. Louis, MO, 1998.